Oncology Peer Review On-The-Go: Kami Maddocks, MD, on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL

News
Podcast

CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.

CancerNetwork® spoke with Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, about CD19-directed agents, avoiding rechallenging with rituximab (Rituxan), and outcomes with second-line therapy for transplant-ineligible patients with diffuse large B-cell lymphoma.

Visit cancernetwork.com to check out the first episode of this 3-part series here.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Related Content
The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease

Roman Fabbricatore
January 17th 2025
Article

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

Tim Cortese;Ariana Pelosci
January 16th 2025
Article

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

3 Things You Should Know About Immunotherapy in DLBCL

3 Things You Should Know About Immunotherapy in DLBCL

Matthew A. Lunning, MD;Grzegorz S. Nowakowski, MD
December 19th 2024
Article

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Ashley Chan
December 13th 2024
Article

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.